Home › NCT05729607

Vertical Soft Tissue Augmentation With CTG vs ADM

Vertical Soft Tissue Augmentation With Dermal Matrix and Enamel Matrix Derivative vs Connective Tissue Graft for the Treatment of Peri-implant Soft Tissue Dehiscences in the Esthetic Zone: A Randomized, Controlled, Clinical, Trial

Who can join

Ages 18 to 99 · All sexes · Healthy volunteers welcome

Inclusion criteria:

* Age ≥ 18 years
* Periodontally and systemically healthy
* Full-mouth plaque score and full-mouth bleeding score ≤ 20% (measured at four sites per tooth)
* Presence of single functional dental implant in the anterior with a PSTD
* Implants diagnosed as healthy (Berglundh et al., 2018)

Exclusion criteria are:

* Contraindications for surgery
* Systemic condition (e.g. diabetes mellitus, HIV, cancer, etc) that could compromise wound healing
* Patients pregnant or attempting to get pregnant (self-reported)
* Untreated periodontitis
* Untreated peri-implant mucositis or peri-implantitis (Berglundh et al., 2018)
* Smoking, defined as self-reported daily habit. Occasional smokers won't be excluded
* History of soft tissue grafting at the implant site within the last 6 months

About the study

The study aims at comparing two different approaches for vertical soft tissue augmentation at implant sites exhibiting soft tissue dehiscences: autogenous connective tissue graft vs acellular dermal matrix + enamel matrix derivative

What is being tested

• Vertical soft tissue augmentation (procedure)
• Vertical soft tissue augmentation (procedure)

Sponsor: Harvard Medical School (HMS and HSDM) · Participants: 28 · Started: May 26, 2023

Contact the study team

• Lorenzo Tavelli, DDS, MS · Phone: 734-604-4364

Official record on ClinicalTrials.gov — NCT05729607

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.